The pharmacology of antimicrobial therapy can be divided increasing antimicrobial concentrations. Similarly, the MIC does not provide any information on persistent effects of antibacterial into two distinct components (figure 1). The first of these components is pharmacokinetics, or the absorption, distribution, agents-inhibitory effects that persist after exposure to an antimicrobial. These persistent effects include the postantibiotic efand elimination of drugs. These factors, combined with the dosage regimen, determine the time course of drug concentrafect (PAE), the postantibiotic sub-MIC effect (PAE-SME), and the postantibiotic leukocyte enhancement (PALE) [5] [6] [7] . The tions in serum, which in turn determine the time course of drug concentrations in tissues and body fluids. With respect to effect of increasing concentrations on the bactericidal activity of antimicrobials and the magnitude of persistent effects give a antimicrobials, the time course of drug concentrations at the site of infection is of special interest. Pharmacodynamics is the much better description of the time course of antimicrobial activity than is provided by the MIC and MBC. relationship between serum concentration and the pharmacological and toxicological effects of drugs. With respect to antimicrobials, the primary interest is in the relationship between Bactericidal Activity concentration and the antimicrobial effect. The time course of antimicrobial activity is a reflection of the interrelationship Shah et al. [8] were the first investigators to propose that between pharmacokinetics and pharmacodynamics. antibacterials could be divided into different groups on the basis Studies over the past 20 years have demonstrated marked of their patterns of bactericidal activity. The first pattern is chardifferences in the time course of antimicrobial activity among acterized by concentration-dependent killing over a wide range antibacterials [1] [2] [3] . Furthermore, the pattern of antimicrobial of concentrations. The higher the drug concentration, the greater activity over time is an important determinant of effective dosage the rate and extent of bactericidal activity. This pattern is obregimens [4] . This review will focus on the interrelationship served with the aminoglycosides and fluoroquinolones and with between pharmacokinetics and pharmacodynamics in determinexposure of anaerobic bacteria to metronidazole [2, 3, 8]. In ing dosing regimens for different classes of antibacterials. The contrast, the second pattern is characterized by minimal concenability of specific pharmacokinetic/pharmacodynamic parametration-dependent killing. Saturation of the killing rate occurs at ters to predict the efficacy of antibacterial activity in animal low multiples of the MIC-usually around four to five times models of infection and in human infections will be emphasized. the MIC. Concentrations above these values do not kill the organisms any faster or more extensively. Thus, the extent of Pharmacodynamics: Parameters of Antimicrobial killing in this pattern of bactericidal activity is largely dependent Activity on the time of exposure. The absence of major concentrationdependent killing is a common characteristic of b-lactam antibiMICs and MBCs have been the major parameters used to otics, vancomycin, clindamycin, and the macrolides [2, 3, 8, 9] . quantify the activity of an antibacterial drug against the infecting Figure 2 illustrates the effect of increasing drug concentrapathogen. Although these parameters are good predictors of the tions on the in vitro antimicrobial activity of tobramycin, cipotency of the drug-organism interaction, they do not provide profloxacin, and ticarcillin against a standard strain of Pseuany information on the time course of antimicrobial activity. For domonas aeruginosa. Increasing concentrations of tobramycin example, the MBC does not provide information on the rate of and ciprofloxacin were associated with a more rapid and extenbactericidal activity and whether this rate can be enhanced by sive degree of bacterial killing, as exhibited by the steeper slopes of the killing curves. Increased concentrations of ticarcillin, resulted in a change in slope, as the concentration was Received
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Prolongation of sub-MIC concentrations of amikacin by simulating the drug's half-life in humans (2 hours) extended the duration of in vivo PAEs by 40% -100% over values observed Persistent Effects with a dose producing the same area under the concentrationvs.-time curve (AUC) but eliminated with a half-life of 20 PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10] . PAE can be minutes in mice [19] . PALE refers to the observations that bacteria in the postanticonsidered the time it takes for an organism to recover from the effects of exposure to an antimicrobial; this phenomenon biotic phase are more susceptible to intracellular killing or to phagocytosis by leukocytes. This phenomenon can also prolong was first described in the 1940s with regard to the activity of penicillin against staphylococci and streptococci [11 -13], but the duration of the PAE, both in vitro and in vivo [7, 10] . Antimicrobials that produce the longest PAEs tend to exhibit these early observations were not applied to newer drugs and gram-negative organisms until the late 1970s. PAE is demonmaximal effects when exposed to leukocytes. In general, the presence of neutrophils tends to double the duration of the PAE strated in vitro by observing bacterial growth kinetics after a drug is removed.
of aminoglycosides and fluoroquinolones for gram-negative bacilli exposed to these drugs [16, 19] . However, leukocytes have All antibacterials produce PAEs in vitro when susceptible gram-positive bacteria, such as staphylococci and streptococci, no major effect on the minimal in vivo PAEs observed for gram-negative bacilli exposed to b-lactams. are exposed to these drugs [10] . Prolonged PAEs for gramnegative bacilli are observed after exposure to antibacterials Pharmacokinetic and Pharmacodynamic Parameters and that are inhibitors of protein synthesis or nucleic acid synthesis. Efficacy Such drugs include the aminoglycosides, fluoroquinolones, tetracyclines, macrolides, chloramphenicol, and rifampin [10] . In
The pharmacodynamic characteristics described above sugcontrast, short PAEs or no PAEs are observed for gram-negagest that the time course of antimicrobial activity can vary tive bacilli after exposure to b-lactam antibiotics. The only exception to this class has been the carbapenems, such as imipenem and meropenem, which produce prolonged PAEs, primarily with strains of P. aeruginosa [14, 15] .
The PAE has also been demonstrated in vivo in a variety of animal infection models [16] . The neutropenic mouse thighinfection model has been used in most in vivo studies [17] . There are several important differences between the in vivo and in vitro PAE that cause concern about the value of in vitro measurements. First, the length of the in vitro PAE is not predictive of the duration of the in vivo PAE [10, 18] . In most cases, in vivo PAEs are longer than in vitro PAEs. In vivo PAEs of aminoglycosides and fluoroquinolones are further prolonged by the presence of leukocytes and the simulation of human pharmacokinetics [16, 19] . Second, prolonged PAEs Such study designs are rarely used in human clinical trials but are easily performed with animal infection models. Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25 -31] . The results of a study of cefotaxime activity against a standard strain of Klebsiella pneumoniae in the lungs of neutropenic mice are shown in figure 4 . In this study, pairs of mice were treated with multiple dosage regimens of time that serum levels exceeded the MIC were determined and calculated for each dosage regimen. As shown by the scattergrams in figures 4A and 4B, there was a poor relationship markedly for different antibacterial agents. For example, the b-lactams exhibit minimal concentration-dependent killing and between cfus per lung and the peak/MIC and 24-hour AUC/ MIC ratios. On the other hand, a highly significant correlation produce prolonged in vivo PAEs only with staphylococci. High drug levels will not kill organisms more effectively than lower was observed between the number of bacteria in the lungs and the percentage of time that serum levels exceeded the MIC. concentrations. Furthermore, regrowth of most organisms will commence very soon after serum drug levels decrease below
The specific pharmacokinetic/pharmacodynamic parameters correlating with efficacy in animal infection models are listed the MIC. Thus, the goal of a dosing regimen for these drugs would be to optimize the duration of exposure. The duration in table 1. As expected, time above the MIC has consistently been the only pharmacokinetic/pharmacodynamic parameter of time that serum levels exceed the MIC should be the major pharmacokinetic/pharmacodynamic parameter determining the that correlates with the therapeutic efficacy of b-lactam antibiotics. Time above the MIC is also the parameter that correlates in vivo efficacy of the b-lactam antibiotics.
On the other hand, the aminoglycosides and fluoroquinolones with efficacy of the macrolides and clindamycin. For aminoglycosides and fluoroquinolones, the AUC/MIC exhibit major concentration-dependent killing. Infrequent dosing of large doses would also be possible because the prolonged and peak/MIC ratios have been the parameters that correlate with efficacy. Most studies have shown slightly better correlaPAEs would protect against bacterial regrowth when serum levels fall below the MIC. The goal of a dosing regimen for tions with the AUC/MIC ratio than with the peak/MIC ratio. Peak/MIC ratios may be more important in infections where these drugs would be to maximize their concentrations. The peak/MIC and/or AUC/MIC ratios should be the major pharmathere is a significant risk of the emergence of resistant subpopulations [29] . cokinetic/pharmacodynamic parameters correlating with efficacy of the aminoglycosides and fluoroquinolones.
Although vancomycin, the tetracyclines, azithromycin, and quinupristin/dalfopristin do not exhibit concentration-depenThese predictions can be difficult to prove for humans because of the design of most clinical trials. Most studies dent killing, the AUC/MIC ratio has been the major pharmacokinetic/pharmacodynamic parameter correlating with the theraevaluating the efficacy of different dosage regimens compare two or more dose levels of drug administered at the same peutic efficacy of these drugs. This result may be due to the much longer in vivo PAEs produced by these drugs than by dosing interval. As shown in the left panel of figure 3 , a fourfold-higher dose produces a higher peak/MIC ratio, a the b-lactams, clindamycin, and other macrolides [9, 10] . Because most infections occur in tissues and the common higher AUC/MIC ratio, and a longer duration of time above the MIC. If the higher dose produces a better therapeutic bacterial pathogens are extracellular, interstitial fluid concentrations at the site of infection should be the prime determinants effect than the lower dose, it is difficult to determine which pharmacokinetic/pharmacodynamic parameter is of major of efficacy. Drug concentrations in serum (or plasma) are much better predictors of interstitial fluid levels than are tissue hoimportance, as all three increase. However, much of the interdependence among pharmacokinetic/pharmacodynamic pamogenate concentrations. Tissue homogenates mix the interstitial, intracellular, and vascular compartments together. Use of rameters can be reduced by comparing the results of dosage regimens that are based on different dosing intervals. As the tissue homogenate concentration tends to result in an underestimation or overestimation of the interstitial fluid concentrashown in the right panel of figure 3 , a dose administered every 2 hours, compared with a fourfold-higher dose given tion, depending on the ability of the drug to accumulate intracellularly. every 8 hours, resulted in a lower peak/MIC ratio but a longer / 9c43$$ja84
11-24-97 19:57:27 cida UC: CID Studies with use of subcutaneously implanted cotton threads have demonstrated that drug concentrations in the interstitial fluid of tissues show little lag in penetration and are very close to drug levels in serum [32, 33] . However, 
Magnitude of the Pharmacokinetic/Pharmacodynamic Parameter Required for Efficacy
Because pharmacokinetic/pharmacodynamic parameters can correct for differences in pharmacokinetics and intrinsic antibacterial activity, it is likely that the magnitude of these parameters required for efficacy would be similar in different animal species. If this were the case, the results from studies in animal infection models could be used as a guide for establishing human dosage regimens. This would be especially helpful in designing dosage regimens for new antibacterials and in situations where it is difficult to readily obtain sufficient clinical data (e.g., infections due to emerging resistant organisms or 
b-Lactams
Time above the MIC is the pharmacokinetic/pharmacodyintermediate and penicillin-resistant strains were used in several studies. The mortality was virtually 100% if serum levels namic parameter that correlates with the therapeutic efficacy of the various b-lactam antibiotics. Studies in animal infection were above the MIC for £20% of the dosing interval. In contrast, as soon as the duration of time that serum levels exceeded models have demonstrated that antibiotic concentrations do not need to exceed the MIC for 100% of the dosing interval to the MIC was §40% -50% of the dosing interval, survival was on the order of 90% -100%. exert a significant antibacterial effect [25 -27, 36] . As shown in figure 4 (the efficacy of cefotaxime against K. pneumoniae To assess the relationship between efficacy and the time above MIC in a clinical situation, bacteriologic cure in patients in the lungs of neutropenic mice), an in vivo bacteriostatic effect was observed when serum levels were above the MIC with acute otitis media has been selected as a sensitive indicator of successful clinical response. There have been a reasonable for 30% -40% of the dosing interval, whereas maximum killing was approached when levels were above the MIC for 60% -number of clinical trials that have included routine repeated tympanocentesis of middle ear fluid after 2 -7 days of therapy 70% of the time. Very similar times above MIC percentages have been observed in murine thigh-and lung-infection models to determine whether the infecting organism was eradicated [39 -42] . Figure 6 demonstrates the relationship between time of several broad-spectrum cephalosporins against gram-negative bacilli and streptococci, providing unbound drug levels above the MIC and the bacteriologic cure rate for many b-lactams against S. pneumoniae and Haemophilus influenzae were used for assessing the efficacy of highly protein-bound cephalosporins such as ceftriaxone [25] .
in patients with otitis media [38, 43] . In general, a time above the MIC of ú40% was required to achieve an 85% -100% The percentages for time above the MIC were slightly lower for the penicillins, and lower again for the carbapenems, when bacteriologic cure rate. The impact of penicillin resistance in S. pneumoniae on the these drugs were assessed against the same types of organisms [37] . These differences reflect the variation in rate of killing, ability of standard dosage regimens of three oral and four parenteral b-lactams to provide free-drug concentrations above which is fastest with the carbapenems and slowest with the cephalosporins. In addition, for staphylococci, the time above the MIC 50 and MIC 90 for §40% -50% of the dosing interval is shown in table 2. Among the three oral dosage regimens for the MIC required for efficacy is less than that observed for gram-negative bacilli and streptococci. This difference is due children, amoxicillin and cefuroxime would provide adequate durations above MIC for penicillin-intermediate strains, while to the prolonged in vivo PAEs observed for staphylococci exposed to b-lactams but not for gram-negative bacilli and strepcefaclor would not. For penicillin-resistant strains, only amoxicillin would provide levels above the MIC for §40% of the tococci exposed to these drugs. Figure 5 incorporates all the available data from the pubdosing interval. These estimates have recently been shown to predict efficacy for cefaclor, cefuroxime axetil, and amoxicillished studies in which mortality was used as an end point and in which animals infected with S. pneumoniae were treated for lin/clavulanate in patients infected with drug-resistant S. pneumoniae strains who were entered in clinical trials where bacteriseveral days with penicillins or cephalosporins [38] . Penicillin-/ 9c43$$ja84
11-24-97 19:57:27 cida UC: CID clinical outcome of therapy for osteomyelitis. As shown in table 3 , an analysis of the data for patients who received only b-lactam antibiotics demonstrates that the presence of a detectable trough serum bactericidal titer was an important determinant for cure of the infection [48] . All patients for whom therapy failed had undetectable trough bactericidal titers of trials have documented the success of this type of dosage regimen [49] . Current clinical trials are designed to determine if continuous infusion will allow for the use of lower daily drug ologic cure or clinical cure were used as end points [42, 44, dosages than those required for intermittent administration or 45]. All four of the parenteral b-lactams provide serum levels will improve efficacy against bacteria with reduced susceptibilthat exceed the MIC 90 for resistant strains for ú40% of the ity. For example, early results with continuous infusion of large dosing interval. Thus, it is not surprising that treatment with doses of ampicillin have demonstrated success against moderthese drugs in a large number of patients with severe pneumoately ampicillin-resistant strains (ampicillin MIC Å 32-64 coccal pneumonia did not result in any difference in outcome mg/mL) of vancomycin-resistant Enterococcus faecium [50] . for patients infected with penicillin-resistant strains than for those infected with susceptible isolates [46] .
Slow-growing bacteria in infection sites that require the use Fluoroquinolones of antimicrobial agents with bactericidal activity for efficacy, such as endocarditis and osteomyelitis, may require longer duThe 24-hour AUC/MIC ratio is the parameter that best correlates with the efficacy of the fluoroquinolones [25, 26, 51] . In rations of effective serum concentrations of agents than do acute respiratory tract infections. Weinstein and co-workers animal infection models, the magnitude of this pharmacokinetic/pharmacodynamic parameter required to produce a bacte-[47] correlated the results of the serum bactericidal test with 
Aminoglycosides
In animal infection models, the 24-hour AUC/MIC ratio exhibits a higher correlation with therapeutic efficacy than the peak/MIC ratio. However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56] . To obtain a clinical response of §90%, the peak level needed to exceed the MIC by eightfold to 10-fold. The once-daily dosage regimen for aminoglycosides was designed to enhance peak serum concentrations. As with fluoroquinolones, peak concentrations that are eight to 10 times higher than the MIC can reduce the rate of emergence of aminoglycosideresistant mutants during therapy [55] . Initial exposure of bacteria to the aminoglycosides down-regulates subsequent uptake incidence of nephrotoxicity and ototoxicity associated with the use of aminoglycosides. Uptake of these drugs into renal tubular cells and the endolymph of the ear is more efficient with riostatic effect is Ç35 [27] . This value implies that the AUC averages Ç1.5 times the MIC over a 24-hour period (i.e., 1.5 low sustained concentrations than with high intermittent levels [58, 59] . 1 24 Å 36). This value is independent of the dosing interval, the fluoroquinolones used, and the site of infection.
Although numerous clinical trials have evaluated the efficacy and toxicity of once-daily vs. multiple-daily dosage regimens, The relationship between the 24-hour AUC/MIC values and mortality, as reported in the literature for those studies where inconclusive results on the advantages or disadvantages of the once-daily regimen have been obtained because of the sizes animals were treated for §2 days, survival results were reported at the end of therapy, and pharmacokinetic data were and designs of most of these studies. This has led to multiple provided, is illustrated in figure 7 [27] . Studies of pneumonia and peritonitis and sepsis, performed in mice, rats, and guinea pigs with use of various strains of gram-positive and gramnegative bacteria, were included. In general, 24-hour AUC/ MIC ratios of õ30 were associated with ú50% mortality, whereas AUC/MIC values of §100 were associated with almost no mortality. Thus, it appears that fluoroquinolone concentrations in serum need to average about four times the MIC for each 24 hours (i.e., 4 1 24 Å 96) to produce virtually 100% survival in a variety of experimental animal infections.
A similar relationship has been observed between the 24-hour AUC/MIC ratio and the therapeutic efficacy of fluoroquinolones in clinical trials. As illustrated in figure 8, Forrest et al. [52] found that a 24-hour AUC/MIC value of §125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin. Lower values resulted ratio of 8 -10 has also been shown both in vitro and in vivo / 9c43$$ja84
11-24-97 19:57:27 cida UC: CID meta-analyses, including a recent review of the previous metaemerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug developanalyses [60] . The results of these studies suggest a small, nonsignificant trend towards better efficacy and lower nephroment should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile. toxicity with the once-daily dosage regimen. Other studies have demonstrated that the onset of nephrotoxicity is delayed for several days when the drug is administered once-daily rather 
